on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.
NEWS: Novimmune sponsors Akin Foundation '700 Miles to Hope' bicycle ride, October 4 through 10
Novimmune announced that it will be a Supporting Sponsor of the Matthew and Andrew Akin Foundation "700 Miles to Hope" bicycle ride to benefit the HLH Center of Excellence at Cincinnati Children's Hospital Medical Center in Ohio. (24 SEP 2014)
NEWS: Novimmune appoints Adrian Mills as Chief Business Officer and member of the Executive Committee
Novimmune announced that veteran GlaxoSmithKline executive Adrian Mills has joined the company as Chief Business Officer and member of the Executive Committee. (10 SEP 2014)
NEWS: Novimmune announces the successful completion of Phase I clinical trial for NI-0101
Novimmune announced the successful completion of a comprehensive Phase I clinical trial investigating the pharmacokinetics, pharmaco-dynamics, preliminary tolerability and safety of NI-0101, a first-in-class monoclonal antibody against toll-like receptor 4 (TLR4). (05 AUG 2014)